UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR
REGISTRATION UNDER SECTION 12(b) OF THE
SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-31668
INTEGRATED BIOPHARMA, INC.
THE AMERICAN STOCK EXCHANGE
(Exact name of Issuer as
specified in its charter,
and name of Exchange
where security is listed
and/or registered)
225 Long Ave.,
Hillside, New Jersey 07205
(973) 926-0816
(Address, including zip code, and telephone number, including area
code, of Issuer's principal executive offices)
Common Stock, $0.002 par value per share
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to
strike the class of securities from listing and registration:
[ ] 17 CFR 240.12d2-2(a)(1)
[ ] 17 CFR 240.12d2-2(a)(2)
[ ] 17 CFR 240.12d2-2(a)(3)
[ ] 17 CFR 240.12d2-2(a)(4)
[ ] Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules
to strike the class of securities from listing and/or withdraw registration on
the Exchange.
|X| Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of
the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the
voluntary withdrawal of the class of securities from listing and registration on
the Exchange.
Pursuant to the requirements of the Securities Exchange Act of 1934, Integrated
BioPharma, Inc. certifies that it has reasonable grounds to believe that it
meets all of the requirements for filing the Form 25 and has caused this
notification to be signed on its behalf by the undersigned duly authorized
person.
February 5, 2007 By: /s/ Dina Masi Chief Financial Officer
---------------- ----------------- -----------------------
Date Name Title